Self‐Propelled In Situ Polymerized Nanoparticles Activating the STING Pathway for Enhanced Bladder Cancer Immunotherapy
Advanced Science · 2025
DOI: 10.1002/advs.202502750 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Lei Peng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Lanzhou University Second Hospital, Lanzhou, 730000, P. R. China. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Immunotherapy, Nanoparticles, Membrane Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shenzhen Science and Technology Innovation Commission, Shenzhen Science and Technology Program.
Abstract (Originalsprache)
Bladder cancer, a common malignancy of the urinary tract, presents complex therapeutic challenges, thereby necessitating the exploration of innovative treatment strategies. This study introduces a novel, self‐propelled nanomedicine delivery system that forms nanoparticles within the bladder lumen by co‐infusing dopamine hydrochloride, Mn 2+ , cGAMP, and urease into the bladder to initiate in situ polymerization. The resulting Mn‐cGAMP@PDA‐urease (DMCU) nanoparticles possess a urease‐modified surface, which acts as an engine to generate propulsive force by breaking down urea. Consequently, this process enhances nanoparticle retention in the bladder mucosa and facilitates efficient drug delivery. The self‐assembled nanoparticles activate the STING pathway, promoting dendritic cell maturation and activation of T cells, thereby enhancing anti‐tumor immune responses. These nanoparticles remain in the bladder for an extended period, significantly improving therapeutic efficacy by sustaining drug release and reducing adverse side effects. In vivo, experiments using a mouse orthotopic model of bladder cancer demonstrate that the DMCU system enhances tumor suppression and immune activation compared with conventional therapies. This novel approach integrates nanotechnology with immunomodulation to address chemotherapy resistance and improve therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Lanzhou University Second Hospital, Lanzhou, 730000, P. R. China.
- Department of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen, 518116, P. R. China.
- Department of Urology, The Fourth Affiliated Hospital of Soochow University, Medical Center of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, 215000, P. R. China.
ORCID-Profile: Lei Peng, Shaohua Zhang
Förderung
- National Natural Science Foundation of China
- Shenzhen Science and Technology Innovation Commission
- Shenzhen Science and Technology Program
- Shenzhen Engineering Research Center
- Sanming Project of Medicine in Shenzhen
- Shenzhen Medical Research Fund
- Science, Technology and Innovation Commission of Shenzhen Municipality
- Shenzhen Science and Technology Innovation Program
Zitieren
APA
Peng, L., Zhao, A., Li, R., Liu, Y., Tang, D., Deng, D., Zhuang, Q., Liang, R., Zhang, S., & Wu, S. (2025). Self‐Propelled In Situ Polymerized Nanoparticles Activating the STING Pathway for Enhanced Bladder Cancer Immunotherapy. Advanced Science. https://doi.org/10.1002/advs.202502750
Vancouver
Peng L, Zhao A, Li R, Liu Y, Tang D, Deng D, et al. Self‐Propelled In Situ Polymerized Nanoparticles Activating the STING Pathway for Enhanced Bladder Cancer Immunotherapy. Advanced Science. 2025. doi:10.1002/advs.202502750
BibTeX
@article{Peng2025,
author = {Peng, Lei and Zhao, Anguo and Li, Rongkang and Liu, Yujun and Tang, Daitian and Deng, Dashi and Zhuang, Qi and Liang, Rui and Zhang, Shaohua and Wu, Song},
title = {Self‐Propelled In Situ Polymerized Nanoparticles Activating the STING Pathway for Enhanced Bladder Cancer Immunotherapy},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202502750}
}
EUVIMED